Literature DB >> 8250307

Intrathecal sufentanil for labor analgesia--sensory changes, side effects, and fetal heart rate changes.

S E Cohen1, C M Cherry, R H Holbrook, Y Y el-Sayed, R N Gibson, R A Jaffe.   

Abstract

This study was designed to evaluate intrathecal (IT) sufentanil for labor analgesia with respect to sensory changes, side effects, and fetal heart rate (FHR) changes. In Phase I of the study, data regarding duration of analgesia and hemodynamic changes were obtained retrospectively from the labor and anesthetic records of 90 patients who had received IT sufentanil, 10 micrograms in 1 mL of saline, during active labor. In Phase II, an additional 18 parturients who received similar treatment were studied prospectively to document sensory, motor, and hemodynamic changes, as well as the incidence of side effects. In Phase I, analgesia occurred rapidly and lasted 124 +/- 68 min (SD); 19% of patients required no further analgesia before delivery. In Phase II, median time to onset of analgesia was 3 min (range 1-6 min) and mean duration of analgesia was 96 +/- 36 min. Decreased sensation to pinprick and cold occurred within 6 min extending from T4 to L4 (upper and lower median levels) in the majority of patients. All subjects requested additional analgesia within approximately 30 min of recession of sensory changes. Motor strength remained normal throughout. Hypotension (systolic blood pressure [BP] < or = 90 mm Hg or > 20% decrease in systolic BP) occurred in 14% and 11% of patients in Phase I and II, respectively. Perineal itching preceded analgesia in 95% of patients and all subjects experienced mild sedation. FHR changes occurred in 15% of cases but were not associated with adverse neonatal outcome.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250307     DOI: 10.1213/00000539-199312000-00013

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

Review 1.  Intrathecal opioids for combined spinal-epidural analgesia during labour.

Authors:  Peter DeBalli; Terrance W Breen
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Recent developments in analgesia during labour.

Authors:  R E Kan; S C Hughes
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

3.  [The clinical use of spinal opioids, part 1].

Authors:  N Rawal
Journal:  Schmerz       Date:  1996-08-26       Impact factor: 1.107

4.  Progress in analgesia for labor: focus on neuraxial blocks.

Authors:  J Sudharma Ranasinghe; David J Birnbach
Journal:  Int J Womens Health       Date:  2010-08-09

Review 5.  Side Effects and Efficacy of Neuraxial Opioids in Pregnant Patients at Delivery: A Comprehensive Review.

Authors:  Sarah Armstrong; Roshan Fernando
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

6.  The comparative study of intravenous Ondansetron and sub-hypnotic Propofol dose in control and treatment of intrathecal Sufentanil-induced pruritus in elective caesarean surgery.

Authors:  Anahita Hirmanpour; Mohammadreza Safavi; Azim Honarmand; Akram Zavaran Hosseini; Maryam Sepehrian
Journal:  J Res Pharm Pract       Date:  2015 Apr-Jun

7.  Uterine hypertonus and fetal bradycardia occurred after combined spinal-epidural analgesia during induction of labor with oxytocin infusion: A case report.

Authors:  Lingyun Yang; Li Wan; Han Huang; Xiaorong Qi
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

8.  Intraoperative neurological event during cesarean section under spinal anesthesia with fentanyl and bupivacaine: Case report and review of literature.

Authors:  Bikash Ranjan Ray; Dalim Kumar Baidya; Deepak Mathew Gregory; Rani Sunder
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-07

9.  Transient lower cranial nerve palsies following spinal anesthesia with bupivacaine-fentanyl combination for transurethral resection of the prostate.

Authors:  Ali Akhaddar; Mohcine Salami; Youssef Darouassi
Journal:  Pan Afr Med J       Date:  2020-03-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.